Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.

Gonzalez-Villasana V, Gutiérrez-Puente Y, Tari AM.

Oncol Rep. 2013 Sep;30(3):1506-10. doi: 10.3892/or.2013.2549. Epub 2013 Jun 19.

PMID:
23783392
2.

Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion.

González-Villasana V, Nieves-Alicea R, McMurtry V, Gutiérrez-Puente Y, Tari AM.

Oncol Rep. 2012 Mar;27(3):861-6. doi: 10.3892/or.2011.1600. Epub 2011 Dec 21.

PMID:
22200873
3.

JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.

McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK, Tari AM.

Int J Oncol. 2011 Apr;38(4):963-71. doi: 10.3892/ijo.2011.925. Epub 2011 Jan 25.

PMID:
21271218
4.

Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.

Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT.

Mol Cancer Ther. 2010 Nov;9(11):3090-9. doi: 10.1158/1535-7163.MCT-10-0362. Epub 2010 Nov 2.

5.

Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.

Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT.

Lancet Oncol. 2009 Jun;10(6):606-14. doi: 10.1016/S1470-2045(09)70088-9. Review.

PMID:
19482249
6.

Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells.

McMurtry V, Simeone AM, Nieves-Alicea R, Tari AM.

Clin Exp Metastasis. 2009;26(3):197-204. doi: 10.1007/s10585-008-9231-x. Epub 2008 Dec 27.

PMID:
19112600
7.

TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.

Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, Tari AM.

Breast Cancer Res. 2008;10(3):R44. doi: 10.1186/bcr2095. Epub 2008 May 12.

8.

Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression.

Nieves-Alicea R, Colburn NH, Simeone AM, Tari AM.

Breast Cancer Res Treat. 2009 Mar;114(2):203-9. doi: 10.1007/s10549-008-9993-5. Epub 2008 Apr 4.

9.
10.

Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.

Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK.

Cancer Res. 2007 Nov 15;67(22):10976-83. Erratum in: Cancer Res. 2018 Jul 15;78(14):4100.

11.

Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma.

Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, Hess KR, Aldape KD, Kondo S, Kumar R, Kondo Y.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6603-9.

12.

Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts.

Tari AM, Gutiérrez-Puente Y, Monaco G, Stephens C, Sun T, Rosenblum M, Belmont J, Arlinghaus R, Lopez-Berestein G.

Int J Oncol. 2007 Nov;31(5):1243-50.

PMID:
17912453
13.

Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.

Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT.

Breast Cancer Res. 2007;9(4):R41.

14.

Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.

Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM.

Int J Oncol. 2007 Apr;30(4):785-92.

PMID:
17332916
15.

N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.

Simeone AM, Colella S, Krahe R, Johnson MM, Mora E, Tari AM.

Carcinogenesis. 2006 Mar;27(3):568-77. Epub 2005 Sep 30.

PMID:
16199439
16.

Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells.

Tari AM, Simeone AM, Li YJ, Gutierrez-Puente Y, Lai S, Symmans WF.

Lab Invest. 2005 Nov;85(11):1357-67.

17.

Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.

Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ.

Biochem Pharmacol. 2005 Aug 15;70(4):511-9.

PMID:
15982640
18.

N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.

Simeone AM, Deng CX, Kelloff GJ, Steele VE, Johnson MM, Tari AM.

Carcinogenesis. 2005 May;26(5):1000-7. Epub 2005 Feb 3.

PMID:
15695235
20.

KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2.

Zang XP, Siwak DR, Nguyen TX, Tari AM, Pento JT.

Clin Exp Metastasis. 2004;21(5):437-43.

PMID:
15672868
21.
22.

The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells.

Mendoza-Gamboa E, Siwak DR, Tari AM.

Oncol Rep. 2004 Oct;12(4):903-8.

PMID:
15375520
24.

The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.

Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ.

J Pharmacol Exp Ther. 2004 Dec;311(3):1163-70. Epub 2004 Sep 9.

PMID:
15358812
26.

How retinoids regulate breast cancer cell proliferation and apoptosis.

Simeone AM, Tari AM.

Cell Mol Life Sci. 2004 Jun;61(12):1475-84. Review.

PMID:
15197471
27.

Liposomal antisense oligonucleotides for cancer therapy.

Siwak DR, Tari AM, Lopez-Berestein G.

Methods Enzymol. 2004;387:241-53. No abstract available.

PMID:
15172168
28.

Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.

Simeone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M, Tari AM.

Cancer Res. 2004 Feb 15;64(4):1224-8.

29.

Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line.

Gutiérrez-Puente Y, Tari AM, Ford RJ, Tamez-Guerra R, Mercado-Hernandez R, Santoyo-Stephano M, Lopez-Berestein G.

Leuk Lymphoma. 2003 Nov;44(11):1979-85.

PMID:
14738153
30.

HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells.

Siwak DR, Mendoza-Gamboa E, Tari AM.

Int J Oncol. 2003 Dec;23(6):1739-45.

PMID:
14612949
31.
32.

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.

Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC Jr.

J Biol Chem. 2003 Jun 27;278(26):23441-50. Epub 2003 Apr 16.

33.

Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter.

Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G.

J Biol Chem. 2003 May 30;278(22):19995-20005. Epub 2003 Mar 17.

34.
35.

A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide.

Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM.

Mol Cancer Ther. 2002 Oct;1(12):1009-17. Erratum in: Mol Cancer Ther. 2002 Dec;1(14):1366.

36.

Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.

Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ.

J Pharmacol Exp Ther. 2002 Oct;303(1):238-46.

PMID:
12235257
37.

Cyclosporin A enhances the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells.

Lim SJ, Simeone AM, Kim CK, Tari AM.

Int J Cancer. 2002 Sep 20;101(3):243-7.

38.

Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.

Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G.

Oncogene. 2002 Aug 8;21(34):5224-32.

39.

Bcl-2-related antisense therapy.

Gutiérrez-Puente Y, Zapata-Benavides P, Tari AM, López-Berestein G.

Semin Oncol. 2002 Jun;29(3 Suppl 11):71-6. Review.

PMID:
12138400
40.

Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation.

Zapata-Benavides P, Tuna M, Lopez-Berestein G, Tari AM.

Biochem Biophys Res Commun. 2002 Jul 26;295(4):784-90.

PMID:
12127961
41.
43.

Cellular uptake of antisense oligonucleotides.

Tari AM, Lopez-Berestein G.

Curr Opin Investig Drugs. 2001 Oct;2(10):1450-3. Review.

PMID:
11890364
44.

GRB2: a pivotal protein in signal transduction.

Tari AM, Lopez-Berestein G.

Semin Oncol. 2001 Oct;28(5 Suppl 16):142-7. Review.

PMID:
11706405
45.

Modulation of Akt activity by doxorubicin in breast cancer cells.

Tari AM, Mehta A, Lopez-Berestein G.

J Chemother. 2001 Jun;13(3):334-6. No abstract available.

PMID:
11450894
46.

"Mitotic drive" of expanded CTG repeats in myotonic dystrophy type 1 (DM1).

Khajavi M, Tari AM, Patel NB, Tsuji K, Siwak DR, Meistrich ML, Terry NH, Ashizawa T.

Hum Mol Genet. 2001 Apr 1;10(8):855-63.

PMID:
11285251
47.

Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.

Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM.

Oncogene. 2000 Dec 14;19(54):6271-6.

48.

Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins.

Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, López-Berestein G, Andreeff M.

Blood. 2000 Jun 15;95(12):3929-38.

PMID:
10845930
49.

Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively.

Tari AM, Lopez-Berestein G.

Int J Cancer. 2000 Apr 15;86(2):295-7. No abstract available.

50.

Preparation and application of liposome-incorporated oligodeoxynucleotides.

Tari AM.

Methods Enzymol. 2000;313:372-88. No abstract available.

PMID:
10595367

Supplemental Content

Support Center